194 related articles for article (PubMed ID: 22353836)
1. [Orally disintegrating tablets--advantages and drawbacks].
Tho I
Tidsskr Nor Laegeforen; 2012 Feb; 132(4):424-5. PubMed ID: 22353836
[TBL] [Abstract][Full Text] [Related]
2. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
Al-Khattawi A; Mohammed AR
Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
[TBL] [Abstract][Full Text] [Related]
3. [Technical scheme of real-time evaluation of traditional Chinese medicine orally disintegrating tablets].
Qin D; Chen XD; Feng L; Gu JF; Yuan JR; Jia XB
Zhongguo Zhong Yao Za Zhi; 2014 Dec; 39(24):4716-22. PubMed ID: 25898566
[TBL] [Abstract][Full Text] [Related]
4. [Oral disintegrating tablets. A new, modern, solid dosage form].
Popa G; GafiĊ£anu E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):337-42. PubMed ID: 14755937
[TBL] [Abstract][Full Text] [Related]
5. Orally disintegrating dosage forms and taste-masking technologies; 2010.
Douroumis D
Expert Opin Drug Deliv; 2011 May; 8(5):665-75. PubMed ID: 21438776
[TBL] [Abstract][Full Text] [Related]
6. The technologies used for developing orally disintegrating tablets: a review.
Badgujar BP; Mundada AS
Acta Pharm; 2011 Jun; 61(2):117-39. PubMed ID: 21684842
[TBL] [Abstract][Full Text] [Related]
7. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives.
Ghourichay MP; Kiaie SH; Nokhodchi A; Javadzadeh Y
Biomed Res Int; 2021; 2021():6618934. PubMed ID: 34977245
[TBL] [Abstract][Full Text] [Related]
8. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
Comoglu T; Dilek Ozyilmaz E
Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
[TBL] [Abstract][Full Text] [Related]
9. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
Cantor SL; Khan MA; Gupta A
Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
[TBL] [Abstract][Full Text] [Related]
10. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression.
Tafere C; Yilma Z; Abrha S; Yehualaw A
PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014
[TBL] [Abstract][Full Text] [Related]
11. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559
[TBL] [Abstract][Full Text] [Related]
12. Dissolution testing of orally disintegrating tablets.
Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
[TBL] [Abstract][Full Text] [Related]
13. Orally disintegrating systems: innovations in formulation and technology.
Goel H; Rai P; Rana V; Tiwary AK
Recent Pat Drug Deliv Formul; 2008; 2(3):258-74. PubMed ID: 19075912
[TBL] [Abstract][Full Text] [Related]
14. Effect of granule properties on rough mouth feel and palatability of orally disintegrating tablets.
Kimura S; Uchida S; Kanada K; Namiki N
Int J Pharm; 2015 Apr; 484(1-2):156-62. PubMed ID: 25681720
[TBL] [Abstract][Full Text] [Related]
15. Bitterness evaluation of intact and crushed Vesicare orally disintegrating tablets using taste sensors.
Haraguchi T; Miyazaki A; Yoshida M; Uchida T
J Pharm Pharmacol; 2013 Jul; 65(7):980-7. PubMed ID: 23738725
[TBL] [Abstract][Full Text] [Related]
16. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook.
Elwerfalli AM; Ghanchi Z; Rashid F; Alany RG; ElShaer A
Curr Drug Deliv; 2015; 12(6):652-67. PubMed ID: 25760951
[TBL] [Abstract][Full Text] [Related]
17. Orally disintegrating mini-tablets (ODMTs)--a novel solid oral dosage form for paediatric use.
Stoltenberg I; Breitkreutz J
Eur J Pharm Biopharm; 2011 Aug; 78(3):462-9. PubMed ID: 21324357
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
19. Taste masking microspheres for orally disintegrating tablets.
Xu J; Bovet LL; Zhao K
Int J Pharm; 2008 Jul; 359(1-2):63-9. PubMed ID: 18455893
[TBL] [Abstract][Full Text] [Related]
20. Conceptualisation, Development, Fabrication and In Vivo Validation of a Novel Disintegration Tester for Orally Disintegrating Tablets.
Koner JS; Rajabi-Siahboomi AR; Missaghi S; Kirby D; Perrie Y; Ahmed J; Mohammed AR
Sci Rep; 2019 Aug; 9(1):12467. PubMed ID: 31462654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
